CORDIS · PREVALUNG EU
Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception.
- Код
PREVALUNG EU- Програма
- HORIZON
- Процедура
HORIZON-HLTH-2022-STAYHLTH-02-01- Статус
- SIGNED
- Период
- 01.12.2022 – 30.11.2027
Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис
Участници
| Организации | Роля | Държава | Безвъзмездна помощ |
|---|---|---|---|
| INSTITUT GUSTAVE ROUSSY | координатор | FR | 2 444 708 € |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | участник | FR | 796 855 € |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | участник | NL | 726 375 € |
| UNIVERSITA DEGLI STUDI DI TORINO | участник | IT | 600 625 € |
| МЕДИЦИНСКИ УНИВЕРСИТЕТ-ВАРНА "ПРОФ. Д-Р ПАРАСКЕВ ИВ.СТОЯНОВ" | участник | BG | 450 625 € |
| OLINK PROTEOMICS AB | участник | SE | 427 452 € |
| BIO-ME AS | участник | NO | 393 849 € |
| CENTRE HOSPITALIER REGIONAL DE MARSEILLE ASSISTANCE PUBLIQUE-HOPITAUX MARSEILLE | участник | FR | 377 494 € |
| FONDATION HOPITAL SAINT JOSEPH | участник | FR | 364 610 € |
| KATHOLIEKE UNIVERSITEIT LEUVEN | участник | BE | 328 531 € |
| PATIENTS EN RESEAU | участник | FR | 105 000 € |
| GUSTAVE ROUSSY TRANSFERT | трета страна | FR | 0 € |
| UNIVERSITY COLLEGE LONDON | асоцииран партньор | UK |
Описание
Cardiovascular disease (CVD) and lung cancer (LC) are leading causes of deaths and intertwined chronic inflammatory processes associated with metabolism reprogramming, clonal hematopoiesis of indeterminate potential (CHIP), intestinal dysbiosis, and maladaptive immunity. CVD prone-tobacco users exhibit a 1-2% yearly incidence of LC. Low dose computed tomography screening programs reduce LC mortality by 20%. Beyond epidemiological scores, risk identification, early cancer detection and interception are mostly based on cell autonomous approaches. Understanding pathophysiological failures linking CVD to LC would allow to take steps for prevention. Based on metabolo-metageno-proteo-immuno-gen-omics, our PREVALUNG prospective study conducted in CVD tobacco consumers allowed to unveil four drivers of early carcinogenesis leading to actionable biomarkers that can be harnessed to pioneer personalized interceptive measures. Four main objectives will be harnessed by 7 academic partners (transdisciplinarity and trialists in interception), 3 diagnostic Biotech Cies and one nutrition Foundation. First, refine and validate in retro- and pro-spective cohorts (>60.000), the 4 classifiers relying on the 4 inflammatory drivers (autophagy/innate immunity/intestinal barrier defects and CHIP) to implement patient stratification. Second, develop and validate robust friendly-user tools monitoring such biomarkers for routine risk assessment. Third, demonstrate the actionability of these biomarkers through a biologically-informed multi-arm randomised trial testing measures targeting each of the 4 main drivers of inflammation using food supplements or pharmacological agents (metformin, anti-NKG2A/PDL-1 Abs, IL-1 inhibitor, probiotics respectively) in addition to diet and life-style changes to return to homeostasis. Fourth, to adapt a secured interface between patients and clinical researchers using these new tools to the longitudinal monitoring of the interceptive measures.
Официални данни · CORDIS · синхронизирано 17.10.2026 10:16 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).